初治结核病患者中贝达喹啉耐药率高及维拉帕米的有效性。
High Prevalence of Bedaquiline Resistance in Treatment-Naive Tuberculosis Patients and Verapamil Effectiveness.
机构信息
Department of Mycobacteriology and Pulmonary Research, Pasteur Institute of Iran, Tehran, Iran.
Microbiology Research Center (MRC), Pasteur Institute of Iran, Tehran, Iran.
出版信息
Antimicrob Agents Chemother. 2019 Feb 26;63(3). doi: 10.1128/AAC.02530-18. Print 2019 Mar.
Abstract
In the regions where bedaquiline (BDQ) is introduced into the regimen, analysis of MIC and screening for preexisting resistance mutations could be crucial. The high prevalence of isolates with high BDQ MICs without prior exposure to BDQ was worrisome. It was also concluded that efflux pumps play a pivotal role in intrinsic BDQ resistance; therefore, the potential of verapamil as an adjunctive therapy to combat BDQ resistance should be investigated.
摘要
在引入贝达喹啉（BDQ）的地区，分析 MIC 和筛查预先存在的耐药突变可能至关重要。高比例的分离株在没有事先接触 BDQ 的情况下就具有高 BDQ MIC 值令人担忧。研究还得出结论，外排泵在 BDQ 的固有耐药中起关键作用；因此，应研究维拉帕米作为辅助治疗来对抗 BDQ 耐药的潜力。
相似文献
1
High Prevalence of Bedaquiline Resistance in Treatment-Naive Tuberculosis Patients and Verapamil Effectiveness.
Antimicrob Agents Chemother. 2019 Feb 26;63(3). doi: 10.1128/AAC.02530-18. Print 2019 Mar.
2
The importance of heteroresistance and efflux pumps in bedaquiline-resistant Mycobacterium tuberculosis isolates from Iran.
Ann Clin Microbiol Antimicrob. 2024 Apr 25;23(1):36. doi: 10.1186/s12941-024-00694-3.
3
Acquired resistance of Mycobacterium tuberculosis to bedaquiline.
PLoS One. 2014 Jul 10;9(7):e102135. doi: 10.1371/journal.pone.0102135. eCollection 2014.
4
Verapamil Increases the Bioavailability and Efficacy of Bedaquiline but Not Clofazimine in a Murine Model of Tuberculosis.
Antimicrob Agents Chemother. 2017 Dec 21;62(1). doi: 10.1128/AAC.01692-17. Print 2018 Jan.
5
Verapamil increases the bactericidal activity of bedaquiline against Mycobacterium tuberculosis in a mouse model.
Antimicrob Agents Chemother. 2015 Jan;59(1):673-6. doi: 10.1128/AAC.04019-14. Epub 2014 Oct 20.
6
Emergence of mmpT5 Variants during Bedaquiline Treatment of Mycobacterium intracellulare Lung Disease.
J Clin Microbiol. 2017 Feb;55(2):574-584. doi: 10.1128/JCM.02087-16. Epub 2016 Dec 7.
7
Defining Bedaquiline Susceptibility, Resistance, Cross-Resistance and Associated Genetic Determinants: A Retrospective Cohort Study.
EBioMedicine. 2018 Feb;28:136-142. doi: 10.1016/j.ebiom.2018.01.005. Epub 2018 Jan 9.
8
Acquisition of clofazimine resistance following bedaquiline treatment for multidrug-resistant tuberculosis.
Int J Infect Dis. 2021 Jan;102:392-396. doi: 10.1016/j.ijid.2020.10.081. Epub 2020 Oct 29.
9
Variants associated with Bedaquiline (BDQ) resistance identified in Rv0678 and efflux pump genes in Mycobacterium tuberculosis isolates from BDQ naïve TB patients in Pakistan.
BMC Microbiol. 2022 Feb 25;22(1):62. doi: 10.1186/s12866-022-02475-4.
10
Bedaquiline susceptibility test for totally drug-resistant tuberculosis Mycobacterium tuberculosis.
J Microbiol. 2017 Jun;55(6):483-487. doi: 10.1007/s12275-017-6630-1. Epub 2017 Apr 20.
引用本文的文献
1
Prevalence of bedaquiline resistance in patients with drug-resistant tuberculosis: a systematic review and meta-analysis.
BMC Infect Dis. 2025 May 12;25(1):689. doi: 10.1186/s12879-025-11067-2.
2
Verapamil and its metabolite norverapamil inhibit the MmpS5L5 efflux pump to increase bedaquiline activity.
Proc Natl Acad Sci U S A. 2025 Apr 22;122(16):e2426827122. doi: 10.1073/pnas.2426827122. Epub 2025 Apr 17.
3
Direct thin-layer agar for bedaquiline-susceptibility testing of at BSL2 level yields high accuracy in 15 days from sputum processing.
J Clin Microbiol. 2025 Apr 9;63(4):e0180624. doi: 10.1128/jcm.01806-24. Epub 2025 Mar 3.
4
Molecular mechanisms of resistance and treatment efficacy of clofazimine and bedaquiline against .
Front Med (Lausanne). 2024 Jan 10;10:1304857. doi: 10.3389/fmed.2023.1304857. eCollection 2023.
5
Antimicrobial drug resistant features of Mycobacterium tuberculosis associated with treatment failure.
PLoS One. 2023 Oct 26;18(10):e0293194. doi: 10.1371/journal.pone.0293194. eCollection 2023.
6
Dodecanoic acid & palmitic acid disarms rifampicin resistance by putatively targeting mycobacterial efflux pump Rv1218c.
Indian J Med Res. 2023 Feb-Mar;157(2&3):192-203. doi: 10.4103/ijmr.ijmr_1610_22.
7
Intra-Host Evolution Among Drug-Resistant Tuberculosis Patients Failing Treatment.
Infect Drug Resist. 2023 May 9;16:2849-2859. doi: 10.2147/IDR.S408976. eCollection 2023.
8
The implication of Mycobacterium tuberculosis-mediated metabolism of targeted xenobiotics.
Nat Rev Chem. 2023 May;7(5):340-354. doi: 10.1038/s41570-023-00472-3. Epub 2023 Mar 20.
9
The evolution of antibiotic resistance is associated with collateral drug phenotypes in Mycobacterium tuberculosis.
Nat Commun. 2023 Mar 18;14(1):1517. doi: 10.1038/s41467-023-37184-7.
10
Variants in Bedaquiline-Candidate-Resistance Genes: Prevalence in Bedaquiline-Naive Patients, Effect on MIC, and Association with Mycobacterium tuberculosis Lineage.
Antimicrob Agents Chemother. 2022 Jul 19;66(7):e0032222. doi: 10.1128/aac.00322-22. Epub 2022 Jun 27.
本文引用的文献
1
Genetic Diversity of Multi- and Extensively Drug-Resistant Mycobacterium tuberculosis Isolates in the Capital of Iran, Revealed by Whole-Genome Sequencing.
J Clin Microbiol. 2019 Jan 2;57(1). doi: 10.1128/JCM.01477-18. Print 2019 Jan.
2
Defining Bedaquiline Susceptibility, Resistance, Cross-Resistance and Associated Genetic Determinants: A Retrospective Cohort Study.
EBioMedicine. 2018 Feb;28:136-142. doi: 10.1016/j.ebiom.2018.01.005. Epub 2018 Jan 9.
3
Bedaquiline Resistance: Its Emergence, Mechanism, and Prevention.
Clin Infect Dis. 2018 May 2;66(10):1625-1630. doi: 10.1093/cid/cix992.
4
MmpS5/MmpL5 as an efflux pump in Mycobacterium species.
Tuberculosis (Edinb). 2017 Dec;107:13-19. doi: 10.1016/j.tube.2017.08.001. Epub 2017 Aug 4.
5
Examination of bedaquiline- and linezolid-resistant Mycobacterium tuberculosis isolates from the Moscow region.
J Antimicrob Chemother. 2017 Jul 1;72(7):1901-1906. doi: 10.1093/jac/dkx094.
6
Primary Clofazimine and Bedaquiline Resistance among Isolates from Patients with Multidrug-Resistant Tuberculosis.
Antimicrob Agents Chemother. 2017 May 24;61(6). doi: 10.1128/AAC.00239-17. Print 2017 Jun.
7
Rapid emergence of bedaquiline resistance: lessons to avoid repeating past errors.
Eur Respir J. 2017 Mar 22;49(3). doi: 10.1183/13993003.01719-2016. Print 2017 Mar.
8
Synergistic Interactions of MmpL3 Inhibitors with Antitubercular Compounds .
Antimicrob Agents Chemother. 2017 Mar 24;61(4). doi: 10.1128/AAC.02399-16. Print 2017 Apr.
9
Unexpected high prevalence of resistance-associated Rv0678 variants in MDR-TB patients without documented prior use of clofazimine or bedaquiline.
J Antimicrob Chemother. 2017 Mar 1;72(3):684-690. doi: 10.1093/jac/dkw502.
10
A Multilaboratory, Multicountry Study To Determine Bedaquiline MIC Quality Control Ranges for Phenotypic Drug Susceptibility Testing.
J Clin Microbiol. 2016 Dec;54(12):2956-2962. doi: 10.1128/JCM.01123-16. Epub 2016 Sep 21.
Zotero 插件